Does my BDNF actually go up after a ketamine infusion?

In animal studies, yes. Autry and colleagues showed a clear, rapid spike in hippocampal BDNF protein in mice within an hour of a sub-anesthetic ketamine dose. The human data is messier. Some studies of serum or plasma BDNF in patients show small post-infusion increases, others show no change, and serum BDNF is a noisy proxy for what's happening in the brain. We do not measure BDNF in clinical practice and you should be skeptical of any clinic that promises a specific number.

Is BDNF the whole reason ketamine works?

No. BDNF is one important node in a longer chain. The current model includes a glutamate surge, AMPA receptor activation, mTOR signaling, dendritic spine growth, and changes in functional connectivity. Other ideas, including effects on the opioid system and on inflammation, are still being studied. We try not to oversell any single piece of the mechanism.

Does exercise raise BDNF too, so could I just exercise?

Yes, regular aerobic exercise reliably raises BDNF and we recommend it for anyone with depression who can tolerate it. For severe treatment-resistant depression, exercise alone is rarely enough. The mechanisms appear to be complementary, not interchangeable. Patients who respond to ketamine often find that exercise becomes more accessible afterward, which may help sustain the gains.

Will ketamine grow my brain back?

That is the kind of phrase we try to avoid. The honest version is that animal research shows ketamine restores synaptic density in regions that get pruned by chronic stress, and human imaging hints at related changes. That is not the same as growing new brain. Synapses are connections between cells, not new cells. The framing matters because overpromising sets people up to feel cheated when results are real but more modest.

Why does the antidepressant effect happen so fast?

Standard antidepressants take weeks because their effects on synaptic function depend on slow, indirect downstream changes. Ketamine appears to trigger BDNF release, mTOR signaling, and new synaptic protein synthesis within hours of a single dose. That is why response can show up within twenty-four hours in patients who are going to respond. The trade-off is that the initial effect is also shorter-lived, which is why most protocols use a series of infusions.

Ketamine and BDNF: The Brain-Growth Signal Behind the Antidepressant Effect

What BDNF actually is, in plain English

BDNF stands for brain-derived neurotrophic factor. It is a small protein the brain makes to keep neurons healthy, encourage them to form new connections, and help existing connections get stronger when they are used. You can think of it as the brain’s grow-and-connect signal. When BDNF is around in healthy amounts, neurons sprout new dendritic spines, synapses mature, and circuits stay plastic enough to learn. When BDNF is chronically low, the opposite happens: spines retract, synapses thin out, and circuits get rigid in ways that look a lot like the brain changes seen in long-running depression.

BDNF acts mostly through a receptor called TrkB. When BDNF binds TrkB, it sets off a cascade of intracellular signals that ultimately tell the cell to make more synaptic protein, build more spines, and strengthen specific connections. That cascade is one of the main hardware mechanisms behind learning, memory, and recovery from stress. It is also one of the cleanest links between molecular biology and the everyday experience of feeling like your brain is working again.

Why depression and chronic stress lower BDNF

Decades of animal and post-mortem human work have converged on the same general picture. Chronic stress raises cortisol and excitatory glutamate transmission in stress-sensitive regions like the prefrontal cortex and hippocampus. Sustained over weeks and months, that environment is toxic to dendritic spines and synapses. Spines retract. BDNF expression drops. The hippocampus, on average, shrinks slightly in people with long-running depression. Functional connectivity in mood-regulating circuits looks blunted on imaging.

Sanacora, Treccani and Popoli laid out an influential version of this argument in Neuropharmacology in 2012, framing depression as, in part, a disorder of glutamate and synaptic plasticity. In their telling, stress lowers BDNF and synaptic density, and any treatment that reverses those changes — not just one that nudges serotonin — should help. That framing set the stage for taking ketamine’s antidepressant effect seriously as a plasticity story rather than a curiosity.

This is also why “feeling stuck” is such a recurring complaint in depression. The neural hardware for forming new associations and trying new behavior gets quieter. People are not imagining it. Depression is, among other things, a state of reduced plasticity, and BDNF sits near the center of that story.

Autry 2011: the experiment that put BDNF at the center

The cleanest single piece of evidence linking ketamine to BDNF came in 2011. Autry and colleagues, working in Lisa Monteggia’s lab, published a paper in Nature showing several things at once.

First, a single sub-anesthetic dose of ketamine produced rapid antidepressant-like behavior in mice in standard tests of stress response. Second, within roughly an hour of that dose, hippocampal tissue showed a measurable increase in BDNF protein. Third, and this is the part that made the paper a landmark, the antidepressant-like behavioral effect was abolished in two separate genetic conditions: mice with BDNF knocked out in the relevant brain regions, and mice with the TrkB receptor knocked out. Take BDNF or its receptor offline and ketamine stops working in these animals.

Crucially, the BDNF surge appeared to depend on new protein being made on the spot. Ketamine blocks NMDA receptors on inhibitory interneurons, briefly disinhibits glutamate transmission, and in the process appears to lift a translational brake on BDNF synthesis. That is a tidy mechanism: a single dose, a fast burst of a known plasticity protein, and behavior that depends on the plasticity protein doing its job.

How ketamine triggers a BDNF burst

The current working model, refined by many groups since 2011, goes something like this. Ketamine preferentially blocks NMDA receptors on a class of inhibitory interneurons. With those interneurons quieted, glutamate output from nearby pyramidal neurons rises briefly. That glutamate surge activates AMPA receptors on the receiving neurons. AMPA activation triggers BDNF release and TrkB activation. TrkB activation switches on mTOR, the master regulator of protein synthesis. mTOR drives the production of new synaptic proteins, and within hours dendritic spines start to form and existing synapses get stronger.

Li and colleagues nailed down a critical piece of this chain in a 2010 Science paper. They showed that ketamine rapidly activated mTOR signaling in rat prefrontal cortex, increased synaptic protein levels, and increased dendritic spine density. When they blocked mTOR, both the spine growth and the antidepressant-like behavior disappeared. The Autry 2011 work then slotted BDNF into the same chain upstream of mTOR.

Duman, Aghajanian, Sanacora and Krystal pulled this together in a 2016 Nature Medicine review framing rapid-acting antidepressants as a fundamentally different class of drug. Their model centers on stress-reversing synaptic plasticity, with BDNF release as a key downstream step rather than a side effect. The mechanism story in that review is the one most clinicians use today when they talk about why ketamine can do in twenty-four hours what an SSRI cannot do in six weeks.

Where BDNF fits in the bigger ketamine mechanism story

It would be easy to read the above and conclude that BDNF is the answer. It is not. BDNF is one important node in a chain that has several other nodes, and the chain itself is one of several plausible mechanisms running in parallel.

The plasticity model gets the most airtime because it is the most worked out, but other lines of research deserve mention. Some studies have found that opioid system involvement may matter for ketamine’s antidepressant effect in humans, though that finding is contested. Anti-inflammatory effects, changes in default-mode network connectivity, and effects on the lateral habenula have all been proposed as additional pieces. Different mechanisms may dominate in different patients, or even in the same patient across different infusions.

There is also an honesty problem about animal-versus-human evidence. The cleanest BDNF data — Autry 2011, Li 2010, the knockout work that followed — comes from rodents. Human studies of serum or plasma BDNF after ketamine have produced mixed results, partly because peripheral BDNF is a noisy stand-in for what is happening inside the brain. Imaging studies in humans show plausibly related changes in prefrontal connectivity and gray matter, but linking those changes specifically to BDNF in any given patient is not yet possible. The mechanism is real and is one of several. Promising it as “the” mechanism overstates the evidence.

You can read more about the broader mechanism work, including the human imaging evidence, in our overview of what brain research has shown about ketamine.

What this does and doesn’t mean for patients

For someone considering ketamine for treatment-resistant depression, here is the practical translation.

The reason ketamine can work within twenty-four hours is that BDNF release, mTOR signaling, and new synaptic protein synthesis happen on a timescale of hours, not weeks. That is a real biological difference from SSRIs and SNRIs, and it lines up with what patients describe when they respond. People will say something lifted, or that they could feel their brain making connections again. The molecular story is consistent with that experience.

The reason ketamine’s effect can fade over days to weeks is that the synaptic gains require maintenance. Without continued reinforcement — from repeat infusions, behavioral activation, therapy, sleep, exercise — the new connections weaken again, especially in a brain that is still living inside the same stress environment. This is part of why we and most clinicians frame the period after an infusion as a neuroplastic window to be used, not a one-shot fix.

One more important piece. Ketamine is FDA-approved as an anesthetic; its use for depression and other psychiatric conditions is off-label. The FDA-approved psychiatric ketamine product is intranasal esketamine (Spravato), approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation. IV ketamine for depression, anxiety, PTSD, and pain remains an off-label use, and any clinic claiming otherwise is being loose with the regulatory facts.

We do not measure BDNF in our patients, and you should not expect a clinic to. Serum BDNF varies with time of day, exercise, recent meals, and assay technique. A single number tells you very little. The mechanism is interesting and helps explain why response often shows up so quickly, but it is not a lab value to chase.

What we tell patients in Nashville about “brain-growth” claims

You will sometimes see ketamine marketed with phrases like “regrows your brain” or “reverses depression’s damage.” We try to be more careful than that, because the evidence is interesting enough on its own without the embellishment. Research suggests ketamine restores synaptic density in regions that get pruned by chronic stress. Studies indicate this happens through a chain that involves a glutamate surge, AMPA activation, BDNF release, TrkB and mTOR signaling, and new synaptic protein synthesis. Data shows that the behavioral effect, in animals, depends on those steps working.

That is not the same as growing new brain. Most of what changes is connections between existing cells, not the cells themselves. The framing matters, because patients who arrive expecting an overnight transformation are set up to feel cheated when they get a real but more modest improvement. Patients who arrive expecting a meaningful neuroplastic opening — one that has to be used — tend to do better with the protocol over time.

If you want to understand how an infusion course actually works at our clinic, that walks through the practical side. The short version: Marla Peterson, CRNA, oversees every infusion and provides anesthesia-level monitoring throughout, in a quiet private room with continuous vitals, and a series of sessions over two to three weeks is typical for the initial course. At $475 per session, the protocol is a real financial commitment, and we would rather have an honest conversation about that up front than oversell the underlying biology.